IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug?

Future Oncol. 2018 Apr;14(10):897-899. doi: 10.2217/fon-2017-0667. Epub 2018 Mar 12.
No abstract available

Keywords: IFN-α; bevacizumab; neuroendocrine tumors; randomized trials; targeted therapies.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bevacizumab / therapeutic use
  • Guidelines as Topic
  • Humans
  • Interferon-alpha / therapeutic use*
  • Molecular Targeted Therapy
  • Neuroendocrine Tumors / drug therapy*
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents
  • Interferon-alpha
  • Bevacizumab